MTAP-DELETED SOLID TUMORS
Clinical trials for MTAP-DELETED SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new MTAP-DELETED SOLID TUMORS trials appear
Sign up with your email to follow new studies for MTAP-DELETED SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat cancers with missing MTAP gene
Disease control Recruiting nowThis study tests a new oral drug called S095035, alone or with another drug (TNG462), in adults with advanced solid tumors that have a specific gene deletion (MTAP). These cancers have not responded to at least one prior treatment. The goal is to see if the drug is safe and can s…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for Hard-to-Treat cancers: first human trial of PEP08 begins
Disease control Recruiting nowThis early-phase study tests a new drug called PEP08 in people with advanced solid tumors that have a specific genetic change (MTAP deletion). The main goals are to check safety, find the right dose, and see if the drug shows signs of shrinking tumors. About 40 adults who have tr…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1 • Sponsor: PharmaEngine • Aim: Disease control
Last updated May 08, 2026 12:02 UTC
-
New targeted drug shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called BAY 3713372 in people with solid tumors that lack a gene called MTAP. The drug works by blocking a protein that helps these cancer cells grow, while leaving normal cells alone. The main goals are to check the drug's safety, how the body processe…
Matched conditions: MTAP-DELETED SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 08, 2026 12:02 UTC